Select Medical (NYSE:SEM) Issues FY 2025 Earnings Guidance

Select Medical (NYSE:SEM) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 1.090-1.190 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $5.4 billion-$5.6 billion, compared to the consensus revenue estimate of $5.8 billion.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SEM. UBS Group lowered their target price on shares of Select Medical from $40.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, January 3rd. StockNews.com lowered shares of Select Medical from a “buy” rating to a “hold” rating in a report on Thursday, February 13th. Benchmark lowered Select Medical from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. Finally, Royal Bank of Canada lifted their price target on Select Medical from $40.00 to $47.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $39.50.

Select Medical Stock Performance

Shares of SEM stock traded down $0.15 during trading hours on Thursday, hitting $19.11. The company’s stock had a trading volume of 975,271 shares, compared to its average volume of 792,814. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 1.37. The company has a 50 day moving average of $19.14 and a 200 day moving average of $28.14. Select Medical has a 12-month low of $18.02 and a 12-month high of $40.98. The stock has a market cap of $2.47 billion, a PE ratio of 8.93, a price-to-earnings-growth ratio of 0.64 and a beta of 1.45.

Select Medical (NYSE:SEM) last announced its quarterly earnings results on Thursday, February 20th. The health services provider reported $0.18 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.11). Select Medical had a return on equity of 15.99% and a net margin of 3.97%. On average, sell-side analysts forecast that Select Medical will post 1.97 EPS for the current fiscal year.

Insider Buying and Selling at Select Medical

In other news, Director Marilyn B. Tavenner sold 32,000 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $21.09, for a total transaction of $674,880.00. Following the sale, the director now directly owns 22,000 shares of the company’s stock, valued at $463,980. This represents a 59.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert G. Breighner, Jr. sold 4,989 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $19.95, for a total value of $99,530.55. Following the completion of the transaction, the vice president now directly owns 30,356 shares of the company’s stock, valued at $605,602.20. The trade was a 14.12 % decrease in their position. The disclosure for this sale can be found here. 19.14% of the stock is currently owned by corporate insiders.

Select Medical Company Profile

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra.